Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
(R)-AM1241 binds to cannabinoid (CB) receptors and has greater than 100-fold selectivity for the CB2 over the CB1 receptor (Kis = 15 and 5,000 nM, respectively, in a membrane assay using human receptors).1 (R)-AM1241 acts as an agonist at human CB2 receptors (EC50 = 118 nM) but an inverse agonist at rat and mouse CB2 receptors (EC50s = 315 and 341 nM, respectively). Similar to the racemate AM1241 (Item No. 10010118), (R)-AM1241 produces antinociception to thermal, but not mechanical, pain in rats.2 The pain-reducing effect of (R)-AM1241 is blocked by the CB2-specific inhibitor SR 144528 (Item No. 9000491) but not by either the CB1-selective inhibitor rimonabant (Item No. 9000484) or the opioid receptor blocker naloxone (Item No. 15594 | ISO60191).
WARNING This product is not for human or veterinary use.
1. Species-
2. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: Lack of dependence upon opioid receptor activation. AAPS J. 12(2), 147-157 (2010).
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-